ANNEX 1 27 In the context of its initial public offering, GenSight Biologics unrealized gains of €33 K. The number of shares purchased implemented a liquidity agreement. As of December 31, 2017: amounts to 233,068 at an average purchase price of €5.62 and • Long-term deposits consisted of free cash available within this the number of shares sold amounts to 215,182 at an average liquidity agreement; selling price of €5.69. • Own shares amount to €193 K and are composed of 36,625 shares valued at the year-end rate (€6.18), adjusted by NOTE 4 — RECEIVABLES Breakdown of receivables is summarized in the following table: In thousands of euros Less than one year More than one year Total gross Prepayments 240 — 240 Accounts receivable and related receivables 257 — 257 Research tax credit, “CICE” 3,698 — 3,698 VAT 538 — 538 Loans and receivables 888 — 888 Prepaid expenses 478 — 478 NET 6,100 — 6,100 Prepayments are made of advances to suppliers. Prepaid expenses correspond mainly to advances on rents, As of December 31, 2017, the Company has receivables mainly research contracts, insurance premiums and travel expenses. resulting from the service agreement contracted with its US- NOTE 5 — SHORT-TERM INVESTMENTS based subsidiary, amounting to €245 K. As of December 31, 2017, the Company had no short-term The Company has a research tax credit amounting to €3,692 K investments (same as of December 31, 2016). and a tax credit for competitiveness and employment of €6 K. In accordance with the legislation in force, the Company is eligible NOTE 6 — SHAREHOLDERS’ EQUITY for immediate reimbursement of this tax claim. 6.1 — Capital social In the context of the inception of its US-based subsidiary, the As of December 31, 2017, share capital amounts to €606 K and parent company granted a cash advance of $1,066 K (€941 K) consists of 24,234,223 ordinary shares with a nominal value of on June and July, 2017. The balance amounts to €888 K as of €0.025. December 31, 2017. Each ordinary share shall carry to holders a proportional part to the benefits and the net assets of the Company. Share class and number 01/01/17 Capital 12/31/17 Share capital of shares Increase in KEuros Ordinary shares 19,409,701 4,824,522 24,234,223 606 TOTAL 19,409,701 4,824,522 24,234,223 606 Capital increase resulting from the issuance of ordinary shares Capital increase resulting from the exercise of warrants (BCE) On June 27, 2017, the Company operated a capital increase On January 11, 2017, a holder of: whose gross proceeds amounted to €22.5 mil lion, by means • BCE 2013-02 exercised 117,320 BCE 2013-02 representing of a private placement reserved to a category of persons. The 117,320 shares issued; Company issued 3,750,000 ordinary shares with a nominal value • BCE 2015-06 exercised 13,432 BCE 2015-06 representing of €0.025 and a share premium of €5.975 per share. 13,432 shares issued; 250 – GENSIGHT BIOLOGICS – 2017 Registration Document